Placebo (for gefapixant)

DRUG3 trials

Sponsors

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Conditions

Refractory Chronic Cough

Phase 2

A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)

CompletedNCT02349425

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Refractory Chronic Cough

Start: 2015-03-09End: 2016-02-09Updated: 2020-10-22

An 8-Week Refractory Chronic Cough Study (MK-7264-021)

CompletedNCT02612623

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Refractory Chronic Cough

Start: 2015-12-17End: 2016-05-18Updated: 2019-11-25

A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)

CompletedNCT02612610

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Refractory Chronic Cough

Start: 2015-12-15End: 2016-11-04Updated: 2020-06-30

Related Papers

Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough

Therapeutic Advances in Respiratory Disease2022-01-0164 citations

Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.

2021-04-0728 citations

Validation of a visual analog scale for assessing cough severity in patients with chronic cough

Therapeutic Advances in Respiratory Disease2021-01-0199 citations

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough

ERJ Open Research2020-10-0153 citations

Patient characteristics and triggers eliciting refractory chronic cough

World Allergy Organization Journal2020-08-01

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.

2020-02-25165 citations

Characterization of chronic cough patients participating in a phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist

2019-09-28

Relationship between health-related quality of life and objective cough frequency in a phase 2b trial of gefapixant

2019-09-28

Baseline patient burden in chronic cough from a Phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist

2019-09-28

The effect of baseline factors on treatment response with MK-7264, a P2X3 antagonist, in refractory chronic cough.

2018-09-152 citations

Patient characteristics and triggers eliciting refractory chronic cough

2018-09-151 citations